Aeglea BioTherapeutics (NASDAQ: [[ticker:AGLE]]), an Austin biotech company, announced late Thursday that David Lowe has resigned as the company’s president, CEO and director, effective immediately, according to a press release. Anthony Quinn has been appointed to serve as interim chief executive officer while the company conducts a comprehensive search for a permanent chief executive officer. Lowe led Aeglea from its preclinical-stage to today; the company has three ongoing clinical trials in rare genetic disease and cancer, the company stated. Lowe was also at the helm of the company during its initial public offering in 2016.
Author: Angela Shah
Angela Shah was formerly the editor of Xconomy Texas. She has written about startups along a wide entrepreneurial spectrum, from Silicon Valley transplants to Austin transforming a once-sleepy university town in the '90s tech boom to 20-something women defying cultural norms as they seek to build vital IT infrastructure in a war-torn Afghanistan. As a foreign correspondent based in Dubai, her work appeared in The New York Times, TIME, Newsweek/Daily Beast and Forbes Asia.
Before moving overseas, Shah was a staff writer and columnist with The Dallas Morning News and the Austin American-Statesman. She has a Bachelor's of Journalism from the University of Texas at Austin, and she is a 2007 Knight-Wallace Fellow at the University of Michigan. With the launch of Xconomy Texas, she's returned to her hometown of Houston.
View all posts by Angela Shah
